# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 9 | 6.6 | 136.6 | (62.3-259.3) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 1.5 | 390.9 | (142.7-850.8) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 16 | 21.0 | 76.2 | (43.5-123.7) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 28 | 21.1 | 132.8 | (88.2-192.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

265

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 7.7 | 104.5 | (45.0-205.9) |  | Male | 5 | 5.3 | 94.9 | (30.6-221.3) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 0 | 3.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 4.7 | 126.4 | (46.1-275.0) |
| Female | 37 | 28.8 | 128.4 | (90.4-177.0) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 8.7 | 114.4 | (54.8-210.4) |  |  |  |  |  |  |
| Female | 5 | 6.7 | 75.0 | (24.2-175.1) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 23 | 28.9 | 79.5 | (50.4-119.2) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.8 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.3 | 180.7 | (66.0-393.4) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 3 | 6.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 9 | 6.4 | 139.7 | (63.7-265.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 14.1 | 78.2 | (39.0-139.9) |  | Male | 93 | 108.3 | 85.8 | (69.3-105.2) |
| Female | 10 | 11.6 | 86.5 | (41.4-159.0) |  | Female | 82 | 90.9 | 90.2 | (71.8-112.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

266

# Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 34.8 | 112.0 | (79.6-153.1) |  | Male | 25 | 23.4 | 106.6 | (69.0-157.4) |
| Female | 10 | 15.9 | 62.9 | (30.1-115.7) |  | Female | 26 | 23.5 | 110.7 | (72.3-162.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 7.5 | 159.8 | (82.5-279.1) |  | Male | 4 | 7.2 | nc | (nc-nc) |
| Female | 5 | 7.2 | 69.2 | (22.3-161.4) |  | Female | 12 | 7.2 | 166.6 | (86.0-291.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 36 | 21.2 | 170.2 | (119.2-235.6) |
| Female | 188 | 177.2 | 106.1 | (91.4-122.4) |  | Female | 25 | 22.5 | 111.2 | (71.9-164.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 17.2 | 98.6 | (57.4-157.9) |
| Female | 3 | 6.2 | nc | (nc-nc) |  | Female | 12 | 9.5 | 125.9 | (65.0-220.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 39.3 | 106.8 | (77.0-144.4) |  |  |  |  |  |  |
| Female | 40 | 48.4 | 82.7 | (59.0-112.6) |  | Female | 10 | 16.0 | 62.3 | (29.8-114.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 18 | 9.4 | 191.8 | (113.6-303.2) |  | Male | 11 | 12.5 | 88.2 | (44.0-157.8) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 17 | 16.0 | 106.2 | (61.8-170.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 151 | 120.4 | 125.4 | (106.2-147.1) |
| Female | 7 | 3.2 | 215.6 | (86.4-444.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 20.2 | 114.1 | (72.3-171.3) |  | Male | 13 | 8.4 | 155.4 | (82.7-265.7) |
| Female | 17 | 14.0 | 121.5 | (70.7-194.5) |  | Female | 3 | 6.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 5.5 | 90.8 | (29.3-212.0) |  | Male | 6 | 6.8 | 88.5 | (32.3-192.7) |
| Female | 4 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 14.8 | 108.2 | (61.8-175.6) |  | Male | 11 | 10.0 | 110.2 | (54.9-197.1) |
| Female | 16 | 13.2 | 121.0 | (69.1-196.5) |  | Female | 37 | 34.7 | 106.5 | (75.0-146.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 12.6 | 126.5 | (72.3-205.5) |  |  |  |  |  |  |
| Female | 5 | 5.1 | 97.8 | (31.5-228.2) |  | Female | 45 | 40.8 | 110.4 | (80.5-147.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 73 | 62.1 | 117.6 | (92.2-147.8) |  | Male | 571 | 475.0 | 120.2 | (110.6-130.5) |
| Female | 90 | 82.5 | 109.0 | (87.7-134.0) |  | Female | 624 | 603.2 | 103.5 | (95.5-111.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

267

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 10.5 | 85.4 | (39.0-162.1) |  | Male | 10 | 6.9 | 145.2 | (69.5-267.0) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 6.1 | 81.6 | (26.3-190.4) |
| Female | 42 | 41.0 | 102.5 | (73.9-138.6) |  | Female | 9 | 4.8 | 186.6 | (85.1-354.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 5.3 | 227.7 | (117.5-397.8) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 11.5 | 121.9 | (66.6-204.5) |  |  |  |  |  |  |
| Female | 14 | 10.0 | 139.8 | (76.4-234.6) |  | Female | 9 | 3.6 | 252.5 | (115.2-479.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 1 | 3.8 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 5 | 3.4 | 148.0 | (47.7-345.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 33 | 40.5 | 81.5 | (56.1-114.5) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.1 | 130.7 | (56.3-257.5) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 2 | 7.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 8 | 9.7 | 82.8 | (35.7-163.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 19.6 | 86.7 | (50.5-138.9) |  | Male | 130 | 145.3 | 89.5 | (74.7-106.2) |
| Female | 27 | 18.7 | 144.1 | (95.0-209.7) |  | Female | 151 | 133.1 | 113.4 | (96.0-133.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

268

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 4.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 13 | 22.2 | 58.5 | (31.1-100.1) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 10 | 13.6 | 73.8 | (35.3-135.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

269

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 22.9 | 153.0 | (106.5-212.7) |  | Male | 23 | 14.9 | 154.4 | (97.8-231.6) |
| Female | 6 | 7.6 | 79.3 | (29.0-172.6) |  | Female | 17 | 11.3 | 150.3 | (87.5-240.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 4.5 | 201.4 | (91.9-382.4) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 18 | 13.4 | 134.7 | (79.8-213.0) |
| Female | 111 | 91.9 | 120.8 | (99.4-145.5) |  | Female | 18 | 11.0 | 163.3 | (96.8-258.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 11.3 | 97.4 | (48.5-174.2) |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 8 | 4.8 | 167.8 | (72.2-330.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 25.2 | 67.6 | (39.3-108.2) |  |  |  |  |  |  |
| Female | 25 | 23.0 | 108.6 | (70.3-160.4) |  | Female | 8 | 8.1 | 98.9 | (42.6-195.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.3 | 94.9 | (34.7-206.5) |  | Male | 12 | 8.2 | 145.7 | (75.2-254.5) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 9 | 7.5 | 119.5 | (54.5-226.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 107 | 81.8 | 130.8 | (107.2-158.1) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 13.1 | 84.2 | (42.0-150.6) |  | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 4 | 7.1 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 9.2 | 173.2 | (98.9-281.3) |  | Male | 3 | 5.9 | nc | (nc-nc) |
| Female | 5 | 6.3 | 79.4 | (25.6-185.3) |  | Female | 10 | 16.8 | 59.5 | (28.5-109.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 8.4 | 95.3 | (41.1-187.9) |  |  |  |  |  |  |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 26 | 21.4 | 121.3 | (79.2-177.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 41.5 | 62.7 | (40.9-91.8) |  | Male | 354 | 308.9 | 114.6 | (103.0-127.2) |
| Female | 49 | 41.3 | 118.8 | (87.9-157.0) |  | Female | 331 | 300.5 | 110.1 | (98.6-122.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

270

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 47 | 34.1 | 137.9 | (101.3-183.4) |  | Male | 14 | 21.6 | 64.8 | (35.4-108.8) |
| Female | 23 | 13.2 | 174.0 | (110.3-261.1) |  | Female | 22 | 17.7 | 124.3 | (77.9-188.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 6.0 | nc | (nc-nc) |  | Male | 6 | 6.9 | 87.5 | (32.0-190.5) |
| Female | 9 | 5.5 | 164.8 | (75.2-312.8) |  | Female | 3 | 6.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 24 | 19.0 | 126.2 | (80.8-187.8) |
| Female | 144 | 141.3 | 101.9 | (86.0-120.0) |  | Female | 24 | 18.1 | 132.3 | (84.7-196.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 15.0 | 133.0 | (81.2-205.4) |
| Female | 4 | 4.5 | nc | (nc-nc) |  | Female | 4 | 7.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 48 | 35.6 | 135.0 | (99.5-178.9) |  |  |  |  |  |  |
| Female | 33 | 38.9 | 84.7 | (58.3-119.0) |  | Female | 7 | 12.7 | 55.3 | (22.1-113.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 8.8 | 147.1 | (78.2-251.6) |  | Male | 15 | 11.8 | 127.4 | (71.3-210.2) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 14 | 13.2 | 105.8 | (57.8-177.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 86 | 109.3 | 78.7 | (63.0-97.2) |
| Female | 4 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 17.9 | 139.4 | (90.2-205.7) |  | Male | 8 | 7.9 | 101.1 | (43.5-199.1) |
| Female | 8 | 11.4 | 70.1 | (30.2-138.1) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 5.2 | 134.0 | (53.7-276.1) |  | Male | 10 | 3.9 | 253.7 | (121.5-466.7) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 13.0 | 153.9 | (94.0-237.7) |  | Male | 9 | 7.9 | 114.1 | (52.1-216.6) |
| Female | 4 | 10.3 | nc | (nc-nc) |  | Female | 19 | 23.9 | 79.6 | (47.9-124.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 11.4 | 139.9 | (79.9-227.2) |  |  |  |  |  |  |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 26 | 33.3 | 78.1 | (51.0-114.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 70 | 61.4 | 114.0 | (88.8-144.0) |  | Male | 478 | 434.6 | 110.0 | (100.4-120.3) |
| Female | 90 | 70.7 | 127.2 | (102.3-156.4) |  | Female | 494 | 482.4 | 102.4 | (93.6-111.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

271

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 7 | 13.9 | 50.2 | (20.1-103.5) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 7 | 9.8 | 71.7 | (28.7-147.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

272

# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 22.9 | 96.1 | (60.2-145.5) |  | Male | 36 | 14.4 | 250.7 | (175.5-347.1) |
| Female | 12 | 8.4 | 143.3 | (73.9-250.3) |  | Female | 29 | 11.1 | 261.2 | (174.9-375.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.1 | 145.9 | (53.3-317.6) |  | Male | 5 | 4.6 | 109.0 | (35.1-254.4) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 10 | 12.8 | 78.2 | (37.4-143.8) |
| Female | 99 | 90.8 | 109.0 | (88.6-132.7) |  | Female | 10 | 11.5 | 86.8 | (41.5-159.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 10.4 | 125.4 | (66.7-214.5) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 7 | 4.9 | 142.8 | (57.2-294.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 24.4 | 98.5 | (63.1-146.5) |  |  |  |  |  |  |
| Female | 19 | 25.2 | 75.5 | (45.4-117.8) |  | Female | 7 | 8.1 | 86.9 | (34.8-179.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.0 | 83.1 | (26.8-193.9) |  | Male | 8 | 8.0 | 100.1 | (43.1-197.2) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 7 | 8.4 | 83.6 | (33.5-172.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 67 | 74.9 | 89.5 | (69.3-113.6) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 12.1 | nc | (nc-nc) |  | Male | 5 | 5.3 | 94.0 | (30.3-219.5) |
| Female | 6 | 7.2 | 83.5 | (30.5-181.7) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 8.9 | 112.4 | (53.8-206.8) |  | Male | 1 | 5.2 | nc | (nc-nc) |
| Female | 7 | 6.6 | 106.1 | (42.5-218.6) |  | Female | 18 | 15.0 | 120.2 | (71.2-190.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 20 | 20.9 | 95.5 | (58.3-147.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 36 | 40.7 | 88.5 | (62.0-122.6) |  | Male | 288 | 293.6 | 98.1 | (87.1-110.1) |
| Female | 42 | 43.8 | 95.9 | (69.1-129.7) |  | Female | 318 | 306.6 | 103.7 | (92.6-115.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

273

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 17.2 | 81.2 | (44.4-136.3) |  | Male | 6 | 11.1 | 53.9 | (19.7-117.3) |
| Female | 2 | 5.4 | nc | (nc-nc) |  | Female | 8 | 7.9 | 101.5 | (43.7-200.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 14 | 9.8 | 142.8 | (78.0-239.6) |
| Female | 48 | 63.3 | 75.8 | (55.9-100.5) |  | Female | 5 | 7.7 | 64.5 | (20.8-150.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.0 | 62.3 | (20.1-145.4) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 5 | 3.3 | 150.0 | (48.3-350.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 18.2 | 71.6 | (38.1-122.4) |  |  |  |  |  |  |
| Female | 10 | 16.0 | 62.3 | (29.8-114.6) |  | Female | 7 | 5.6 | 125.9 | (50.4-259.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.7 | nc | (nc-nc) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 9 | 5.4 | 166.2 | (75.9-315.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 40 | 60.0 | 66.7 | (47.6-90.8) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 9.6 | 62.7 | (22.9-136.5) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 0 | 4.9 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.7 | 89.2 | (32.6-194.1) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 11 | 11.4 | 96.5 | (48.1-172.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 11 | 14.8 | 74.3 | (37.0-133.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 32.1 | 62.2 | (38.0-96.1) |  | Male | 156 | 228.1 | 68.4 | (58.1-80.0) |
| Female | 25 | 30.1 | 83.1 | (53.8-122.6) |  | Female | 158 | 210.1 | 75.2 | (63.9-87.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

274

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 17.9 | 66.9 | (34.5-116.8) |  | Male | 11 | 12.1 | 90.7 | (45.2-162.4) |
| Female | 7 | 6.0 | 116.3 | (46.6-239.6) |  | Female | 18 | 9.5 | 189.3 | (112.1-299.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 7 | 3.9 | 181.5 | (72.7-373.9) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 15 | 10.8 | 138.4 | (77.4-228.3) |
| Female | 86 | 77.3 | 111.2 | (88.9-137.3) |  | Female | 8 | 8.9 | 89.5 | (38.6-176.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 9.6 | 62.2 | (22.7-135.5) |
| Female | 0 | 2.7 | nc | (nc-nc) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 20.5 | 63.6 | (33.8-108.7) |  |  |  |  |  |  |
| Female | 9 | 18.8 | 47.8 | (21.8-90.8) |  | Female | 8 | 6.7 | 119.6 | (51.5-235.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  | Male | 9 | 6.7 | 134.7 | (61.5-255.7) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 8 | 6.1 | 132.0 | (56.8-260.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 68 | 71.0 | 95.7 | (74.3-121.3) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 11.1 | 54.2 | (19.8-117.9) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 8 | 5.8 | 137.2 | (59.1-270.4) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 5 | 2.0 | 246.9 | (79.6-576.3) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.3 | 95.3 | (38.2-196.4) |  | Male | 8 | 5.0 | 159.9 | (68.8-315.0) |
| Female | 5 | 5.2 | 96.2 | (31.0-224.5) |  | Female | 26 | 14.7 | 177.0 | (115.6-259.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 7.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 16 | 17.7 | 90.2 | (51.5-146.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 33.5 | 53.7 | (31.8-84.8) |  | Male | 220 | 255.4 | 86.1 | (75.1-98.3) |
| Female | 35 | 32.7 | 107.0 | (74.5-148.8) |  | Female | 261 | 248.3 | 105.1 | (92.8-118.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

275

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 4.8 | 125.0 | (45.7-272.2) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 16 | 16.4 | 97.6 | (55.7-158.5) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 20 | 16.5 | 121.2 | (74.0-187.2) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.0 | 125.4 | (40.4-292.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 8.5 | 58.5 | (18.9-136.6) |  | Male | 56 | 62.2 | 90.0 | (68.0-116.9) |
| Female | 15 | 7.7 | 195.2 | (109.2-322.0) |  | Female | 59 | 53.4 | 110.5 | (84.2-142.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

276

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 4 | 1.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 9 | 11.0 | 82.1 | (37.5-155.9) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 14 | 10.2 | 137.6 | (75.2-230.9) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 6 | 2.6 | 229.3 | (83.7-499.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 40 | 36.6 | 109.2 | (78.0-148.7) |
| Female | 5 | 5.5 | 91.6 | (29.5-213.7) |  | Female | 44 | 37.3 | 118.1 | (85.8-158.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

277

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 5.1 | 156.7 | (67.5-308.8) |  | Male | 5 | 3.2 | 156.0 | (50.3-364.2) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 24 | 19.4 | 123.6 | (79.1-183.8) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 5.5 | 144.7 | (62.3-285.1) |  |  |  |  |  |  |
| Female | 3 | 4.7 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 19 | 16.7 | 113.8 | (68.5-177.7) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 5 | 3.4 | 147.1 | (47.4-343.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 9.0 | 55.5 | (17.9-129.6) |  | Male | 66 | 65.7 | 100.4 | (77.7-127.7) |
| Female | 6 | 8.7 | 69.0 | (25.2-150.3) |  | Female | 63 | 62.4 | 100.9 | (77.6-129.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

278

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 6.0 | 201.4 | (103.9-351.8) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 6 | 1.9 | 314.3 | (114.8-684.0) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 4.3 | 186.7 | (80.4-367.9) |
| Female | 28 | 23.3 | 119.9 | (79.7-173.3) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 4 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 7.7 | 129.3 | (61.9-237.8) |  |  |  |  |  |  |
| Female | 8 | 5.8 | 136.9 | (58.9-269.7) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 27 | 24.0 | 112.3 | (74.0-163.4) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.4 | 136.6 | (49.9-297.3) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 5 | 4.6 | 109.4 | (35.2-255.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 2.7 | 300.5 | (129.4-592.1) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 12 | 5.3 | 227.4 | (117.4-397.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 11.2 | 196.9 | (123.4-298.2) |  | Male | 120 | 93.8 | 127.9 | (106.0-152.9) |
| Female | 11 | 10.3 | 106.4 | (53.0-190.4) |  | Female | 94 | 76.5 | 122.9 | (99.3-150.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

279

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 34.5 | 112.9 | (80.3-154.4) |  | Male | 17 | 22.6 | 75.2 | (43.8-120.5) |
| Female | 14 | 12.5 | 111.7 | (61.0-187.5) |  | Female | 20 | 18.4 | 108.9 | (66.5-168.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 7.0 | 99.4 | (39.8-204.8) |  | Male | 11 | 7.0 | 157.2 | (78.4-281.3) |
| Female | 2 | 5.8 | nc | (nc-nc) |  | Female | 4 | 5.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 29 | 20.5 | 141.5 | (94.8-203.2) |
| Female | 151 | 142.0 | 106.3 | (90.0-124.7) |  | Female | 15 | 17.7 | 84.6 | (47.3-139.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 16.4 | 73.1 | (37.7-127.6) |
| Female | 4 | 5.0 | nc | (nc-nc) |  | Female | 5 | 7.5 | 67.1 | (21.6-156.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 38.3 | 91.3 | (63.6-126.9) |  |  |  |  |  |  |
| Female | 27 | 38.7 | 69.9 | (46.0-101.6) |  | Female | 13 | 12.5 | 104.0 | (55.3-177.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 9.1 | 131.6 | (67.9-229.9) |  | Male | 9 | 12.2 | 73.7 | (33.6-140.0) |
| Female | 5 | 2.4 | 206.1 | (66.4-481.0) |  | Female | 11 | 12.6 | 87.2 | (43.5-156.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 124 | 115.1 | 107.7 | (89.6-128.4) |
| Female | 4 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 28 | 19.5 | 143.9 | (95.6-208.0) |  | Male | 3 | 8.2 | nc | (nc-nc) |
| Female | 11 | 11.2 | 98.6 | (49.2-176.4) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 5.3 | nc | (nc-nc) |  | Male | 6 | 5.3 | 113.7 | (41.5-247.5) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 14.4 | 76.6 | (38.2-137.1) |  | Male | 15 | 9.2 | 162.6 | (90.9-268.2) |
| Female | 15 | 10.6 | 142.0 | (79.4-234.2) |  | Female | 14 | 27.6 | 50.8 | (27.7-85.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 11.8 | 92.8 | (46.3-166.1) |  |  |  |  |  |  |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 27 | 31.1 | 86.8 | (57.2-126.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 59 | 60.7 | 97.2 | (74.0-125.4) |  | Male | 483 | 457.9 | 105.5 | (96.3-115.3) |
| Female | 64 | 66.0 | 97.0 | (74.7-123.9) |  | Female | 445 | 478.4 | 93.0 | (84.6-102.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

280

# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 8 | 8.9 | 90.0 | (38.7-177.3) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 7.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 12 | 25.2 | 47.7 | (24.6-83.3) |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 18 | 28.0 | 64.4 | (38.1-101.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

281

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 24.4 | 102.4 | (66.2-151.1) |  | Male | 11 | 15.1 | 72.9 | (36.4-130.5) |
| Female | 13 | 10.1 | 128.7 | (68.5-220.2) |  | Female | 8 | 12.1 | 66.1 | (28.4-130.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.2 | 118.3 | (38.1-276.0) |  | Male | 1 | 4.7 | nc | (nc-nc) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 5 | 4.4 | 114.6 | (36.9-267.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 13 | 13.4 | 97.1 | (51.7-166.1) |
| Female | 88 | 95.8 | 91.8 | (73.7-113.2) |  | Female | 14 | 13.1 | 107.0 | (58.5-179.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 10.5 | 57.4 | (21.0-125.0) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 7 | 5.3 | 131.0 | (52.5-270.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 25.5 | 90.1 | (57.1-135.2) |  |  |  |  |  |  |
| Female | 30 | 29.6 | 101.3 | (68.3-144.6) |  | Female | 8 | 8.6 | 92.8 | (39.9-182.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 6.2 | 112.6 | (45.1-231.9) |  | Male | 10 | 8.4 | 118.4 | (56.7-217.8) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 15 | 10.2 | 147.1 | (82.3-242.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.6 | nc | (nc-nc) |  | Male | 81 | 77.8 | 104.1 | (82.7-129.4) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 12.5 | 128.2 | (73.2-208.2) |  | Male | 11 | 5.6 | 196.7 | (98.1-352.0) |
| Female | 7 | 8.0 | 87.7 | (35.1-180.8) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 6 | 2.6 | 229.3 | (83.7-499.2) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 9.3 | 128.5 | (66.3-224.4) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 10 | 7.6 | 131.5 | (62.9-241.8) |  | Female | 19 | 15.0 | 126.6 | (76.2-197.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 7.8 | 76.8 | (28.0-167.1) |  |  |  |  |  |  |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 19 | 21.4 | 88.9 | (53.5-138.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 54 | 43.3 | 124.7 | (93.6-162.7) |  | Male | 325 | 307.0 | 105.8 | (94.7-118.0) |
| Female | 40 | 51.6 | 77.6 | (55.4-105.7) |  | Female | 320 | 339.8 | 94.2 | (84.1-105.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

282

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 38 | 49.9 | 76.2 | (53.9-104.6) |  | Male | 30 | 35.8 | 83.9 | (56.6-119.8) |
| Female | 19 | 19.7 | 96.3 | (58.0-150.5) |  | Female | 20 | 34.6 | 57.8 | (35.3-89.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 12.5 | 64.1 | (27.6-126.3) |  | Male | 11 | 10.2 | 107.7 | (53.7-192.7) |
| Female | 13 | 10.5 | 124.4 | (66.2-212.7) |  | Female | 11 | 8.9 | 123.0 | (61.3-220.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 40 | 31.9 | 125.2 | (89.5-170.5) |
| Female | 176 | 227.3 | 77.4 | (66.4-89.8) |  | Female | 21 | 29.4 | 71.5 | (44.2-109.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 25 | 24.0 | 104.3 | (67.5-154.0) |
| Female | 10 | 10.1 | 99.3 | (47.5-182.7) |  | Female | 11 | 12.0 | 91.7 | (45.7-164.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 52 | 56.1 | 92.6 | (69.2-121.5) |  |  |  |  |  |  |
| Female | 48 | 61.4 | 78.2 | (57.7-103.7) |  | Female | 23 | 20.7 | 110.9 | (70.3-166.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 12.9 | 85.6 | (42.6-153.1) |  | Male | 19 | 17.3 | 109.7 | (66.0-171.3) |
| Female | 5 | 3.8 | 130.7 | (42.1-304.9) |  | Female | 21 | 19.8 | 106.1 | (65.6-162.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 11 | 7.5 | 146.9 | (73.3-262.9) |  | Male | 144 | 157.2 | 91.6 | (77.2-107.8) |
| Female | 4 | 6.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 29.1 | 123.8 | (86.7-171.3) |  | Male | 15 | 12.0 | 125.1 | (70.0-206.3) |
| Female | 24 | 18.3 | 131.5 | (84.2-195.7) |  | Female | 14 | 7.9 | 178.0 | (97.3-298.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 7.6 | 145.6 | (72.6-260.5) |  | Male | 7 | 17.5 | 40.1 | (16.1-82.6) |
| Female | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 22.7 | 70.5 | (40.3-114.5) |  | Male | 14 | 17.0 | 82.2 | (44.9-137.9) |
| Female | 20 | 18.1 | 110.2 | (67.3-170.2) |  | Female | 50 | 58.7 | 85.1 | (63.2-112.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 26 | 17.1 | 152.4 | (99.5-223.3) |  |  |  |  |  |  |
| Female | 16 | 6.3 | 252.3 | (144.1-409.8) |  | Female | 48 | 49.4 | 97.2 | (71.7-128.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 105 | 87.5 | 120.0 | (98.1-145.2) |  | Male | 669 | 683.0 | 97.9 | (90.7-105.7) |
| Female | 100 | 103.8 | 96.3 | (78.4-117.1) |  | Female | 723 | 792.0 | 91.3 | (84.8-98.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

283

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 21.0 | 90.6 | (54.5-141.4) |  | Male | 18 | 12.8 | 140.6 | (83.3-222.2) |
| Female | 11 | 8.2 | 134.0 | (66.8-239.7) |  | Female | 10 | 11.1 | 90.4 | (43.3-166.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 9 | 11.4 | 78.8 | (36.0-149.6) |
| Female | 96 | 85.3 | 112.5 | (91.1-137.4) |  | Female | 11 | 11.1 | 98.9 | (49.3-177.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 8.9 | 67.7 | (24.7-147.4) |
| Female | 5 | 2.7 | 183.7 | (59.2-428.7) |  | Female | 6 | 4.6 | 129.6 | (47.3-282.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 22.0 | 95.6 | (59.2-146.2) |  |  |  |  |  |  |
| Female | 32 | 24.0 | 133.1 | (91.0-187.9) |  | Female | 3 | 7.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 3 | 7.2 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 8 | 8.2 | 97.9 | (42.2-192.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 62 | 64.7 | 95.8 | (73.4-122.8) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 10.5 | 66.5 | (26.6-137.0) |  | Male | 5 | 4.8 | 104.0 | (33.5-242.8) |
| Female | 8 | 7.0 | 114.8 | (49.4-226.2) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 3.0 | 197.2 | (72.0-429.2) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 7.9 | 63.7 | (20.5-148.6) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 8 | 6.6 | 121.7 | (52.4-239.8) |  | Female | 11 | 15.4 | 71.4 | (35.6-127.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 26 | 19.5 | 133.2 | (87.0-195.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 36.6 | 101.2 | (71.3-139.5) |  | Male | 239 | 259.9 | 92.0 | (80.7-104.4) |
| Female | 40 | 43.2 | 92.5 | (66.1-126.0) |  | Female | 304 | 295.9 | 102.7 | (91.5-114.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

284

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 6.7 | 74.2 | (23.9-173.0) |  | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 20 | 26.1 | 76.6 | (46.8-118.4) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 7.2 | 97.7 | (39.1-201.3) |  |  |  |  |  |  |
| Female | 9 | 6.2 | 145.2 | (66.3-275.6) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 25 | 23.7 | 105.6 | (68.3-155.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 4 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 1 | 4.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 6 | 6.1 | 98.6 | (36.0-214.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 12.2 | 41.0 | (13.2-95.8) |  | Male | 74 | 90.3 | 81.9 | (64.3-102.8) |
| Female | 13 | 11.9 | 109.5 | (58.2-187.2) |  | Female | 72 | 84.6 | 85.1 | (66.6-107.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

285

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 10.3 | 78.0 | (33.6-153.8) |  | Male | 8 | 6.8 | 118.4 | (51.0-233.3) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 45 | 40.3 | 111.7 | (81.5-149.5) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 5.1 | 116.6 | (42.6-253.7) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 11.6 | 51.8 | (18.9-112.8) |  |  |  |  |  |  |
| Female | 12 | 10.0 | 120.2 | (62.0-209.9) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 3.1 | 159.3 | (51.3-371.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 37 | 35.7 | 103.7 | (73.0-142.9) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 5.9 | 135.5 | (58.3-267.0) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.2 | 119.1 | (38.4-278.0) |  | Male | 5 | 2.7 | 181.9 | (58.6-424.6) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 6 | 7.8 | 77.0 | (28.1-167.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 5 | 8.9 | 55.9 | (18.0-130.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 18.2 | 71.5 | (38.1-122.3) |  | Male | 129 | 138.3 | 93.3 | (77.9-110.8) |
| Female | 18 | 17.1 | 105.2 | (62.3-166.2) |  | Female | 117 | 129.7 | 90.2 | (74.6-108.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

286

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 16.1 | 111.9 | (66.3-176.9) |  | Male | 6 | 10.4 | 57.4 | (21.0-125.0) |
| Female | 10 | 6.6 | 152.3 | (72.9-280.0) |  | Female | 4 | 9.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 10 | 9.4 | 106.9 | (51.2-196.6) |
| Female | 59 | 69.7 | 84.7 | (64.5-109.2) |  | Female | 13 | 9.1 | 143.5 | (76.3-245.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.5 | 134.2 | (64.3-246.8) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 17.5 | 91.7 | (52.4-148.9) |  |  |  |  |  |  |
| Female | 21 | 20.0 | 104.9 | (64.9-160.4) |  | Female | 7 | 6.3 | 111.5 | (44.7-229.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 7 | 5.6 | 124.1 | (49.7-255.7) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 2 | 6.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 50 | 52.1 | 95.9 | (71.2-126.5) |
| Female | 3 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 8.8 | 79.9 | (32.0-164.7) |  | Male | 6 | 3.8 | 158.2 | (57.8-344.4) |
| Female | 10 | 5.6 | 180.0 | (86.2-331.1) |  | Female | 5 | 2.6 | 191.1 | (61.6-446.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 2.5 | 326.3 | (140.5-642.9) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 6.7 | 120.1 | (51.7-236.6) |  | Male | 1 | 4.1 | nc | (nc-nc) |
| Female | 11 | 5.5 | 201.1 | (100.3-359.9) |  | Female | 10 | 13.1 | 76.2 | (36.5-140.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 5.6 | 125.4 | (50.2-258.4) |  |  |  |  |  |  |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 20 | 15.7 | 127.6 | (77.9-197.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 43 | 28.5 | 150.8 | (109.1-203.1) |  | Male | 233 | 210.3 | 110.8 | (97.0-126.0) |
| Female | 28 | 33.0 | 84.8 | (56.3-122.6) |  | Female | 233 | 240.4 | 96.9 | (84.9-110.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

287

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 11.0 | 99.8 | (49.7-178.5) |  | Male | 5 | 7.0 | 71.2 | (22.9-166.2) |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 3 | 5.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 6.3 | nc | (nc-nc) |
| Female | 40 | 42.5 | 94.0 | (67.2-128.0) |  | Female | 6 | 5.6 | 107.8 | (39.4-234.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 11.9 | 67.4 | (29.0-132.8) |  |  |  |  |  |  |
| Female | 11 | 12.4 | 88.8 | (44.3-158.9) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 32 | 35.2 | 91.0 | (62.2-128.4) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.9 | 118.5 | (47.5-244.2) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 4 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.3 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 6 | 3.2 | 186.2 | (68.0-405.3) |  | Female | 5 | 7.6 | 65.7 | (21.2-153.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 8 | 9.4 | 85.4 | (36.8-168.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 19.3 | 98.4 | (59.2-153.6) |  | Male | 117 | 141.7 | 82.6 | (68.3-99.0) |
| Female | 16 | 20.7 | 77.1 | (44.0-125.2) |  | Female | 121 | 146.4 | 82.6 | (68.6-98.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

288

# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 11.2 | 178.3 | (108.9-275.4) |  | Male | 10 | 7.7 | 129.8 | (62.1-238.7) |
| Female | 11 | 4.2 | 263.0 | (131.1-470.5) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.8 | nc | (nc-nc) |
| Female | 46 | 47.5 | 96.9 | (71.0-129.3) |  | Female | 6 | 5.9 | 101.6 | (37.1-221.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 5.8 | 171.5 | (82.1-315.5) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 12.4 | 80.8 | (38.7-148.6) |  |  |  |  |  |  |
| Female | 11 | 12.5 | 87.9 | (43.8-157.2) |  | Female | 1 | 4.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.2 | 155.4 | (50.1-362.7) |  | Male | 5 | 4.1 | 122.6 | (39.5-286.0) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 32 | 42.4 | 75.5 | (51.6-106.6) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 6.9 | 145.9 | (69.8-268.3) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 8 | 3.7 | 215.4 | (92.8-424.5) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 4.7 | 316.8 | (177.2-522.6) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 5 | 3.5 | 141.4 | (45.6-330.0) |  | Female | 6 | 9.0 | 66.7 | (24.4-145.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 4.3 | 140.7 | (51.4-306.2) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 18 | 10.8 | 167.2 | (99.0-264.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 20.9 | 129.0 | (85.0-187.7) |  | Male | 168 | 158.1 | 106.2 | (90.8-123.6) |
| Female | 24 | 22.1 | 108.7 | (69.6-161.7) |  | Female | 170 | 159.5 | 106.6 | (91.2-123.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

289

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 94 | 122.5 | 76.7 | (62.0-93.9) |  | Male | 36 | 81.2 | 44.3 | (31.0-61.4) |
| Female | 40 | 47.7 | 83.9 | (59.9-114.3) |  | Female | 33 | 72.8 | 45.3 | (31.2-63.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 27 | 27.2 | 99.3 | (65.4-144.5) |  | Male | 25 | 25.1 | 99.8 | (64.6-147.3) |
| Female | 22 | 24.0 | 91.7 | (57.5-138.9) |  | Female | 26 | 21.7 | 120.0 | (78.4-175.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 7 | 4.2 | 166.1 | (66.6-342.3) |  | Male | 77 | 73.5 | 104.8 | (82.7-131.0) |
| Female | 512 | 546.6 | 93.7 | (85.7-102.1) |  | Female | 67 | 68.6 | 97.6 | (75.6-124.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 67 | 58.5 | 114.5 | (88.7-145.4) |
| Female | 35 | 19.9 | 175.5 | (122.2-244.1) |  | Female | 20 | 29.0 | 68.9 | (42.1-106.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 150 | 134.8 | 111.3 | (94.2-130.6) |  |  |  |  |  |  |
| Female | 158 | 145.3 | 108.7 | (92.4-127.1) |  | Female | 32 | 49.0 | 65.3 | (44.7-92.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 37 | 32.7 | 113.2 | (79.7-156.1) |  | Male | 48 | 43.3 | 110.7 | (81.6-146.8) |
| Female | 12 | 9.3 | 129.0 | (66.6-225.3) |  | Female | 43 | 47.8 | 89.9 | (65.1-121.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 16 | 12.1 | 132.6 | (75.8-215.4) |  | Male | 388 | 414.2 | 93.7 | (84.6-103.5) |
| Female | 16 | 10.8 | 148.2 | (84.7-240.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 85 | 69.2 | 122.8 | (98.1-151.8) |  | Male | 34 | 29.0 | 117.3 | (81.2-163.9) |
| Female | 51 | 43.3 | 117.8 | (87.7-154.9) |  | Female | 25 | 18.7 | 133.7 | (86.5-197.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 19.0 | 89.5 | (52.1-143.4) |  | Male | 12 | 22.6 | 53.1 | (27.4-92.8) |
| Female | 7 | 6.4 | 109.8 | (44.0-226.1) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 52 | 53.1 | 98.0 | (73.2-128.5) |  | Male | 12 | 33.6 | 35.7 | (18.4-62.4) |
| Female | 41 | 42.0 | 97.5 | (70.0-132.3) |  | Female | 81 | 111.9 | 72.4 | (57.5-90.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 58 | 43.3 | 134.0 | (101.8-173.3) |  |  |  |  |  |  |
| Female | 16 | 15.5 | 103.0 | (58.9-167.3) |  | Female | 120 | 124.0 | 96.8 | (80.2-115.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 253 | 218.7 | 115.7 | (101.8-130.8) |  | Male | 1620 | 1648.6 | 98.3 | (93.5-103.2) |
| Female | 254 | 251.7 | 100.9 | (88.9-114.1) |  | Female | 1758 | 1853.7 | 94.8 | (90.5-99.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

290

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 7.9 | 139.0 | (69.3-248.7) |  | Male | 5 | 5.3 | 94.1 | (30.3-219.7) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.8 | 145.1 | (58.1-299.0) |
| Female | 42 | 33.8 | 124.2 | (89.5-167.9) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 9.1 | 65.8 | (24.0-143.2) |  |  |  |  |  |  |
| Female | 4 | 8.5 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 6 | 2.9 | 207.2 | (75.7-451.0) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 49 | 30.3 | 161.6 | (119.6-213.7) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 4.9 | 143.3 | (57.4-295.3) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 5 | 2.5 | 197.8 | (63.7-461.5) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.3 | 182.7 | (66.7-397.7) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 6 | 6.5 | 92.3 | (33.7-200.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 9 | 7.5 | 120.1 | (54.8-227.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 14.5 | 76.1 | (37.9-136.1) |  | Male | 134 | 111.5 | 120.2 | (100.7-142.3) |
| Female | 18 | 14.1 | 127.8 | (75.7-202.0) |  | Female | 111 | 109.1 | 101.7 | (83.7-122.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

291

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 7 | 1.9 | 362.5 | (145.2-747.0) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 6 | 1.5 | 406.8 | (148.6-885.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 11 | 11.8 | 93.4 | (46.6-167.1) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 8 | 3.8 | 212.0 | (91.3-417.7) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 15 | 10.5 | 143.2 | (80.1-236.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 5.8 | nc | (nc-nc) |  | Male | 45 | 40.1 | 112.2 | (81.8-150.1) |
| Female | 1 | 6.9 | nc | (nc-nc) |  | Female | 48 | 43.0 | 111.7 | (82.4-148.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

292

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 30.5 | 65.5 | (40.0-101.2) |  | Male | 11 | 18.5 | 59.6 | (29.7-106.6) |
| Female | 13 | 10.0 | 129.8 | (69.1-222.0) |  | Female | 14 | 13.4 | 104.7 | (57.2-175.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.1 | 138.0 | (55.3-284.3) |  | Male | 7 | 5.9 | 119.3 | (47.8-245.8) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 5 | 4.5 | 112.1 | (36.1-261.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 16 | 16.4 | 97.4 | (55.7-158.2) |
| Female | 133 | 104.9 | 126.7 | (106.1-150.2) |  | Female | 10 | 13.6 | 73.5 | (35.2-135.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 12.8 | 117.6 | (65.8-193.9) |
| Female | 6 | 3.4 | 175.7 | (64.1-382.4) |  | Female | 8 | 5.7 | 140.1 | (60.3-276.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 36 | 31.6 | 113.9 | (79.8-157.7) |  |  |  |  |  |  |
| Female | 33 | 30.1 | 109.7 | (75.5-154.1) |  | Female | 13 | 9.4 | 138.3 | (73.6-236.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.7 | 90.3 | (36.2-186.2) |  | Male | 6 | 10.5 | 57.1 | (20.9-124.3) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 11 | 10.1 | 108.9 | (54.3-194.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 65 | 96.6 | 67.3 | (51.9-85.8) |
| Female | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 15.1 | 92.6 | (50.6-155.3) |  | Male | 11 | 6.9 | 159.3 | (79.4-285.1) |
| Female | 9 | 8.4 | 107.1 | (48.9-203.3) |  | Female | 5 | 3.9 | 128.0 | (41.2-298.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 3 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 11.5 | 139.4 | (79.6-226.3) |  | Male | 10 | 6.3 | 157.6 | (75.5-289.9) |
| Female | 10 | 7.9 | 126.5 | (60.6-232.7) |  | Female | 21 | 18.2 | 115.2 | (71.3-176.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 9.7 | 62.0 | (22.6-135.0) |  |  |  |  |  |  |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 35 | 23.9 | 146.2 | (101.8-203.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 53.2 | 86.5 | (63.3-115.4) |  | Male | 351 | 378.8 | 92.7 | (83.2-102.9) |
| Female | 52 | 51.2 | 101.5 | (75.8-133.1) |  | Female | 420 | 360.5 | 116.5 | (105.6-128.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

293

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 31.6 | 91.8 | (61.5-131.9) |  | Male | 17 | 20.1 | 84.4 | (49.1-135.1) |
| Female | 13 | 12.6 | 102.9 | (54.7-175.9) |  | Female | 22 | 17.1 | 128.3 | (80.4-194.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.9 | 102.1 | (37.3-222.2) |  | Male | 8 | 6.4 | 125.7 | (54.1-247.8) |
| Female | 8 | 5.2 | 152.4 | (65.6-300.3) |  | Female | 7 | 5.7 | 123.4 | (49.4-254.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 15 | 18.0 | 83.6 | (46.7-137.8) |
| Female | 139 | 136.1 | 102.1 | (85.9-120.6) |  | Female | 20 | 17.4 | 115.0 | (70.2-177.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 14.3 | 97.7 | (53.4-163.9) |
| Female | 6 | 4.5 | 134.4 | (49.1-292.5) |  | Female | 5 | 7.3 | 68.3 | (22.0-159.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 33.7 | 100.9 | (69.8-140.9) |  |  |  |  |  |  |
| Female | 36 | 38.0 | 94.7 | (66.3-131.1) |  | Female | 12 | 12.1 | 99.2 | (51.2-173.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 8.3 | 132.0 | (65.8-236.2) |  | Male | 13 | 11.1 | 117.6 | (62.5-201.1) |
| Female | 5 | 2.5 | 202.8 | (65.4-473.4) |  | Female | 18 | 12.8 | 140.3 | (83.1-221.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 98 | 106.7 | 91.9 | (74.6-112.0) |
| Female | 5 | 1.9 | 269.6 | (86.9-629.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 17.1 | 158.0 | (104.1-229.8) |  | Male | 5 | 7.4 | 67.9 | (21.9-158.4) |
| Female | 15 | 10.8 | 138.4 | (77.4-228.3) |  | Female | 8 | 4.9 | 163.2 | (70.3-321.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 4.9 | 184.8 | (84.3-350.9) |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 12.4 | 104.8 | (55.7-179.2) |  | Male | 9 | 7.6 | 117.8 | (53.7-223.6) |
| Female | 9 | 10.0 | 89.7 | (40.9-170.3) |  | Female | 33 | 23.7 | 139.3 | (95.9-195.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 10.7 | 102.5 | (51.1-183.4) |  |  |  |  |  |  |
| Female | 1 | 4.0 | nc | (nc-nc) |  | Female | 20 | 31.1 | 64.2 | (39.2-99.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 65 | 56.6 | 114.8 | (88.6-146.3) |  | Male | 431 | 412.2 | 104.6 | (94.9-114.9) |
| Female | 56 | 66.0 | 84.8 | (64.1-110.2) |  | Female | 485 | 463.1 | 104.7 | (95.6-114.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

294

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 7.3 | 192.1 | (104.9-322.3) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 34 | 29.2 | 116.4 | (80.6-162.7) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 3.4 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 8.0 | 87.2 | (34.9-179.6) |  |  |  |  |  |  |
| Female | 9 | 6.7 | 133.8 | (61.1-254.1) |  | Female | 6 | 2.5 | 239.5 | (87.5-521.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 35 | 24.5 | 142.6 | (99.3-198.3) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 3 | 5.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 10 | 6.9 | 144.6 | (69.2-266.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 12.9 | nc | (nc-nc) |  | Male | 90 | 95.9 | 93.8 | (75.4-115.3) |
| Female | 10 | 12.3 | 81.1 | (38.8-149.2) |  | Female | 103 | 92.7 | 111.1 | (90.7-134.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

295

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 10.5 | 180.4 | (108.6-281.7) |  | Male | 9 | 6.9 | 130.8 | (59.7-248.4) |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 8 | 5.5 | 144.5 | (62.2-284.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 6.1 | 82.3 | (26.5-192.0) |
| Female | 42 | 44.9 | 93.6 | (67.5-126.5) |  | Female | 5 | 5.6 | 89.7 | (28.9-209.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.1 | 97.7 | (31.5-228.1) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 11.3 | 97.0 | (48.3-173.5) |  |  |  |  |  |  |
| Female | 8 | 11.8 | 68.1 | (29.3-134.1) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 3.9 | 127.0 | (40.9-296.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 40 | 38.2 | 104.8 | (74.9-142.7) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 6.0 | 117.0 | (46.9-241.0) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 7 | 3.6 | 196.2 | (78.6-404.2) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.2 | 118.2 | (38.1-275.8) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 5 | 7.9 | 63.4 | (20.4-148.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 18 | 10.4 | 173.5 | (102.8-274.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 19.4 | 98.2 | (59.1-153.3) |  | Male | 150 | 142.4 | 105.4 | (89.2-123.6) |
| Female | 15 | 21.7 | 69.0 | (38.6-113.8) |  | Female | 135 | 150.4 | 89.8 | (75.3-106.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

296

# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 19.9 | 80.4 | (45.9-130.6) |  | Male | 19 | 13.0 | 145.7 | (87.7-227.6) |
| Female | 0 | 6.1 | nc | (nc-nc) |  | Female | 8 | 9.2 | 87.1 | (37.5-171.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.0 | 150.4 | (54.9-327.3) |  | Male | 5 | 4.2 | 120.5 | (38.8-281.1) |
| Female | 5 | 3.0 | 169.3 | (54.6-395.1) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 10 | 11.6 | 86.0 | (41.2-158.3) |
| Female | 122 | 75.8 | 161.0 | (133.7-192.2) |  | Female | 11 | 8.9 | 123.9 | (61.8-221.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 9.8 | 51.1 | (16.5-119.1) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 21.8 | 114.5 | (74.1-169.1) |  |  |  |  |  |  |
| Female | 14 | 19.0 | 73.8 | (40.3-123.9) |  | Female | 6 | 6.5 | 91.9 | (33.6-200.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 9 | 7.2 | 125.5 | (57.3-238.2) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 3 | 6.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 72 | 71.6 | 100.6 | (78.7-126.7) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 11.5 | 121.7 | (66.5-204.2) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 6 | 5.8 | 103.6 | (37.8-225.5) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 8.1 | 61.8 | (19.9-144.2) |  | Male | 6 | 5.1 | 118.3 | (43.2-257.5) |
| Female | 8 | 5.2 | 154.7 | (66.6-304.7) |  | Female | 17 | 13.8 | 122.8 | (71.5-196.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 16 | 17.1 | 93.6 | (53.5-152.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 36.8 | 27.2 | (13.0-50.0) |  | Male | 228 | 269.5 | 84.6 | (74.0-96.3) |
| Female | 31 | 33.2 | 93.4 | (63.4-132.6) |  | Female | 286 | 245.0 | 116.8 | (103.6-131.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

297

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 18 | 10.9 | 164.9 | (97.7-260.6) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 10 | 11.5 | 86.8 | (41.5-159.6) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.9 | nc | (nc-nc) |  | Male | 33 | 46.1 | 71.6 | (49.3-100.6) |
| Female | 3 | 5.3 | nc | (nc-nc) |  | Female | 31 | 38.7 | 80.1 | (54.4-113.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

298

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 9.3 | 118.7 | (59.2-212.4) |  | Male | 9 | 6.4 | 141.2 | (64.4-268.1) |
| Female | 6 | 2.3 | 264.1 | (96.4-574.8) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 5.7 | 140.1 | (60.3-276.1) |
| Female | 39 | 33.9 | 115.1 | (81.8-157.3) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 5.2 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 10.6 | 66.1 | (26.5-136.2) |  |  |  |  |  |  |
| Female | 8 | 7.0 | 113.6 | (48.9-223.9) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 27 | 37.9 | 71.3 | (47.0-103.8) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.9 | 100.9 | (36.9-219.7) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 6 | 2.5 | 244.4 | (89.3-532.1) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 3.9 | 180.3 | (72.2-371.4) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 7 | 7.1 | 99.1 | (39.7-204.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 14 | 7.9 | 177.4 | (96.9-297.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 17.5 | 108.5 | (65.3-169.4) |  | Male | 127 | 134.6 | 94.3 | (78.6-112.2) |
| Female | 14 | 13.0 | 107.7 | (58.8-180.7) |  | Female | 125 | 104.3 | 119.8 | (99.7-142.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

299

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 16.2 | 160.8 | (105.0-235.6) |  | Male | 14 | 10.1 | 138.7 | (75.8-232.8) |
| Female | 13 | 6.2 | 211.2 | (112.3-361.2) |  | Female | 16 | 8.6 | 187.1 | (106.9-303.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 16 | 9.0 | 177.2 | (101.2-287.7) |
| Female | 83 | 67.3 | 123.4 | (98.3-153.0) |  | Female | 12 | 8.5 | 141.2 | (72.9-246.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.3 | 82.6 | (30.2-179.8) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 17.3 | 92.3 | (52.7-149.9) |  |  |  |  |  |  |
| Female | 19 | 18.7 | 101.7 | (61.2-158.8) |  | Female | 3 | 6.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 6 | 5.6 | 106.3 | (38.8-231.5) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 6 | 6.2 | 97.5 | (35.6-212.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 50 | 52.3 | 95.6 | (70.9-126.0) |
| Female | 3 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 8.5 | 129.8 | (64.7-232.3) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 6 | 5.3 | 112.3 | (41.0-244.4) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.4 | 78.2 | (25.2-182.5) |  | Male | 8 | 3.7 | 216.6 | (93.3-426.8) |
| Female | 8 | 4.9 | 162.1 | (69.8-319.5) |  | Female | 21 | 12.1 | 173.2 | (107.2-264.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 22 | 15.2 | 144.7 | (90.6-219.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 28.2 | 95.7 | (63.1-139.3) |  | Male | 221 | 206.6 | 107.0 | (93.3-122.1) |
| Female | 37 | 31.9 | 115.9 | (81.6-159.8) |  | Female | 286 | 227.7 | 125.6 | (111.4-141.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

300

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 18.4 | 113.9 | (70.5-174.1) |  | Male | 10 | 12.1 | 82.4 | (39.4-151.5) |
| Female | 14 | 7.2 | 193.3 | (105.6-324.4) |  | Female | 4 | 10.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 14 | 10.7 | 130.3 | (71.2-218.7) |
| Female | 73 | 81.6 | 89.5 | (70.1-112.5) |  | Female | 10 | 10.0 | 99.8 | (47.8-183.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 9.1 | 99.2 | (45.2-188.2) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 19.9 | 95.3 | (57.3-148.8) |  |  |  |  |  |  |
| Female | 17 | 21.7 | 78.5 | (45.7-125.7) |  | Female | 5 | 7.1 | 70.0 | (22.6-163.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.1 | 136.4 | (54.7-281.1) |  | Male | 7 | 6.7 | 105.2 | (42.2-216.8) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 7 | 7.2 | 96.9 | (38.8-199.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 85 | 68.3 | 124.4 | (99.4-153.8) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 10.7 | 168.3 | (99.7-266.0) |  | Male | 5 | 4.4 | 113.5 | (36.6-264.9) |
| Female | 5 | 6.4 | 78.1 | (25.2-182.3) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 7.2 | nc | (nc-nc) |  | Male | 2 | 4.8 | nc | (nc-nc) |
| Female | 4 | 5.7 | nc | (nc-nc) |  | Female | 10 | 14.2 | 70.2 | (33.6-129.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.7 | 74.5 | (24.0-173.9) |  |  |  |  |  |  |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 14 | 18.6 | 75.5 | (41.2-126.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 34.2 | 75.9 | (49.6-111.3) |  | Male | 269 | 251.6 | 106.9 | (94.5-120.5) |
| Female | 34 | 38.6 | 88.2 | (61.0-123.2) |  | Female | 238 | 271.5 | 87.7 | (76.9-99.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

301

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 57 | 56.3 | 101.3 | (76.7-131.2) |  | Male | 25 | 37.4 | 66.9 | (43.3-98.7) |
| Female | 22 | 21.1 | 104.3 | (65.4-158.0) |  | Female | 28 | 30.9 | 90.7 | (60.3-131.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 11.5 | 104.3 | (53.9-182.3) |  | Male | 10 | 11.6 | 86.0 | (41.2-158.1) |
| Female | 9 | 9.5 | 94.5 | (43.1-179.5) |  | Female | 14 | 9.6 | 146.4 | (80.0-245.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 2.0 | 254.0 | (81.9-592.7) |  | Male | 38 | 33.4 | 113.7 | (80.5-156.1) |
| Female | 232 | 239.2 | 97.0 | (84.9-110.3) |  | Female | 42 | 29.8 | 141.2 | (101.7-190.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 37 | 27.5 | 134.6 | (94.7-185.5) |
| Female | 10 | 8.4 | 119.1 | (57.0-219.1) |  | Female | 9 | 12.6 | 71.5 | (32.6-135.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 69 | 61.9 | 111.5 | (86.8-141.1) |  |  |  |  |  |  |
| Female | 83 | 64.6 | 128.5 | (102.3-159.3) |  | Female | 16 | 21.2 | 75.5 | (43.1-122.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 15.3 | 104.4 | (59.7-169.6) |  | Male | 27 | 20.0 | 134.7 | (88.7-196.0) |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 24 | 21.2 | 113.0 | (72.4-168.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 9 | 4.7 | 191.7 | (87.5-363.9) |  | Male | 165 | 196.4 | 84.0 | (71.7-97.8) |
| Female | 5 | 3.8 | 133.2 | (42.9-310.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 37 | 32.4 | 114.2 | (80.4-157.5) |  | Male | 13 | 13.4 | 96.9 | (51.6-165.8) |
| Female | 24 | 18.8 | 127.8 | (81.9-190.2) |  | Female | 7 | 8.3 | 84.2 | (33.7-173.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 14 | 9.0 | 155.3 | (84.8-260.6) |  | Male | 10 | 8.6 | 116.1 | (55.6-213.6) |
| Female | 5 | 2.8 | 180.0 | (58.0-420.1) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 23.2 | 81.8 | (49.2-127.7) |  | Male | 21 | 15.2 | 138.4 | (85.6-211.5) |
| Female | 13 | 17.5 | 74.4 | (39.6-127.2) |  | Female | 65 | 45.7 | 142.2 | (109.7-181.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 21 | 20.2 | 104.1 | (64.4-159.1) |  |  |  |  |  |  |
| Female | 6 | 6.7 | 89.6 | (32.7-195.0) |  | Female | 42 | 53.9 | 77.9 | (56.1-105.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 134 | 102.2 | 131.1 | (109.9-155.3) |  | Male | 806 | 760.7 | 106.0 | (98.8-113.5) |
| Female | 126 | 110.0 | 114.5 | (95.4-136.3) |  | Female | 848 | 803.7 | 105.5 | (98.5-112.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

302

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 9.6 | 114.1 | (56.9-204.1) |  | Male | 4 | 6.3 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 0 | 4.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 27 | 36.4 | 74.2 | (48.9-108.0) |  | Female | 5 | 4.3 | 117.3 | (37.8-273.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.9 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 10.5 | 85.5 | (39.0-162.3) |  |  |  |  |  |  |
| Female | 12 | 8.9 | 135.3 | (69.8-236.4) |  | Female | 6 | 3.2 | 189.8 | (69.3-413.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 28 | 37.5 | 74.7 | (49.6-107.9) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 5.7 | 159.1 | (72.6-302.1) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 5 | 6.8 | 73.1 | (23.6-170.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 3.6 | 139.8 | (45.0-326.2) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 11 | 8.4 | 131.1 | (65.4-234.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 17.9 | 106.3 | (64.0-166.0) |  | Male | 115 | 133.4 | 86.2 | (71.2-103.5) |
| Female | 25 | 16.6 | 150.8 | (97.6-222.6) |  | Female | 118 | 118.5 | 99.5 | (82.4-119.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

303

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 29.3 | 133.1 | (94.6-182.0) |  | Male | 16 | 19.8 | 80.9 | (46.2-131.4) |
| Female | 12 | 13.0 | 92.6 | (47.8-161.8) |  | Female | 16 | 17.6 | 90.7 | (51.8-147.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.0 | 115.9 | (46.4-238.8) |  | Male | 4 | 6.1 | nc | (nc-nc) |
| Female | 6 | 5.4 | 110.8 | (40.5-241.3) |  | Female | 6 | 5.8 | 104.3 | (38.1-227.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 21 | 17.6 | 119.6 | (74.0-182.8) |
| Female | 131 | 138.6 | 94.5 | (79.0-112.2) |  | Female | 21 | 17.7 | 118.3 | (73.2-180.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 14.8 | 114.6 | (66.7-183.6) |
| Female | 8 | 4.5 | 175.9 | (75.7-346.6) |  | Female | 8 | 7.4 | 107.6 | (46.3-212.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 32.8 | 103.8 | (71.9-145.0) |  |  |  |  |  |  |
| Female | 31 | 39.0 | 79.4 | (54.0-112.7) |  | Female | 16 | 12.3 | 130.1 | (74.3-211.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 8.1 | 135.5 | (67.5-242.4) |  | Male | 14 | 10.6 | 132.1 | (72.2-221.7) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 8 | 13.1 | 61.0 | (26.3-120.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  | Male | 116 | 105.8 | 109.7 | (90.6-131.6) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 28 | 17.2 | 162.6 | (108.0-235.0) |  | Male | 6 | 7.1 | 84.8 | (31.0-184.6) |
| Female | 11 | 11.0 | 99.6 | (49.6-178.2) |  | Female | 6 | 5.1 | 118.6 | (43.3-258.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.8 | 124.1 | (45.3-270.0) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 12.0 | 216.3 | (141.3-316.9) |  | Male | 6 | 8.1 | 73.9 | (27.0-161.0) |
| Female | 14 | 10.4 | 135.0 | (73.8-226.6) |  | Female | 30 | 24.5 | 122.7 | (82.7-175.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 11.0 | 63.8 | (25.5-131.4) |  |  |  |  |  |  |
| Female | 1 | 4.0 | nc | (nc-nc) |  | Female | 29 | 31.1 | 93.2 | (62.4-133.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 64 | 53.8 | 118.9 | (91.6-151.8) |  | Male | 464 | 403.2 | 115.1 | (104.8-126.0) |
| Female | 79 | 67.6 | 116.9 | (92.6-145.7) |  | Female | 488 | 473.0 | 103.2 | (94.2-112.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

304

# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 3.8 | 156.4 | (57.1-340.3) |  | Male | 8 | 2.7 | 301.8 | (129.9-594.7) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 32 | 18.1 | 176.7 | (120.8-249.4) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 4.3 | 115.8 | (37.3-270.1) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 4 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 20 | 14.0 | 142.8 | (87.2-220.5) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.4 | 113.7 | (36.7-265.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 7.2 | nc | (nc-nc) |  | Male | 70 | 53.8 | 130.2 | (101.5-164.5) |
| Female | 10 | 8.4 | 118.6 | (56.8-218.2) |  | Female | 78 | 59.3 | 131.5 | (103.9-164.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

305

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 9 | 11.2 | 80.7 | (36.8-153.1) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 7.7 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

306

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 8.0 | nc | (nc-nc) |  | Male | 6 | 5.0 | 119.9 | (43.8-261.1) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 4.5 | 133.6 | (48.8-290.8) |
| Female | 27 | 29.1 | 92.8 | (61.2-135.1) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 8.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 8.3 | 72.2 | (26.4-157.1) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 29 | 27.2 | 106.5 | (71.3-152.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.4 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 6 | 6.5 | 92.8 | (33.9-201.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 14.3 | 126.0 | (74.6-199.1) |  | Male | 97 | 103.9 | 93.3 | (75.7-113.9) |
| Female | 17 | 13.5 | 125.7 | (73.2-201.2) |  | Female | 96 | 98.2 | 97.7 | (79.2-119.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

307

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 6.9 | 145.5 | (69.7-267.7) |  | Male | 3 | 5.2 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 6 | 4.4 | 137.4 | (50.2-299.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 10 | 4.7 | 212.0 | (101.5-390.0) |
| Female | 35 | 35.0 | 99.9 | (69.6-138.9) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 8.5 | 165.6 | (90.4-277.8) |  |  |  |  |  |  |
| Female | 11 | 8.1 | 136.4 | (68.0-244.0) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 2.3 | 308.8 | (123.7-636.2) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 22 | 32.2 | 68.4 | (42.8-103.5) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.1 | 97.8 | (31.5-228.3) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 9 | 7.3 | 123.0 | (56.1-233.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 4 | 7.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 13.4 | 104.4 | (57.0-175.1) |  | Male | 117 | 110.7 | 105.7 | (87.4-126.7) |
| Female | 15 | 13.6 | 110.4 | (61.8-182.2) |  | Female | 114 | 109.6 | 104.0 | (85.8-125.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

308

# Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 19 | 11.5 | 164.9 | (99.2-257.4) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 3.4 | 145.1 | (46.8-338.6) |  |  |  |  |  |  |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 6 | 11.5 | 52.1 | (19.0-113.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 6.0 | nc | (nc-nc) |  | Male | 37 | 42.7 | 86.6 | (60.9-119.3) |
| Female | 2 | 5.5 | nc | (nc-nc) |  | Female | 49 | 37.1 | 132.2 | (97.8-174.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

309

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 9.5 | 157.8 | (88.2-260.3) |  | Male | 5 | 7.0 | 71.0 | (22.9-165.7) |
| Female | 7 | 3.7 | 191.6 | (76.8-394.9) |  | Female | 7 | 5.9 | 117.9 | (47.2-243.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 6.4 | nc | (nc-nc) |
| Female | 37 | 47.6 | 77.7 | (54.7-107.0) |  | Female | 3 | 5.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 11.9 | 101.2 | (52.2-176.7) |  |  |  |  |  |  |
| Female | 7 | 11.6 | 60.5 | (24.2-124.6) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 32 | 41.9 | 76.3 | (52.2-107.8) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.7 | 119.2 | (51.3-234.8) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 4.2 | 166.8 | (66.8-343.8) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 8 | 9.4 | 85.3 | (36.7-168.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 4.3 | 164.3 | (65.8-338.5) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 11 | 10.8 | 101.6 | (50.7-181.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 18.1 | 127.3 | (80.7-191.0) |  | Male | 141 | 148.2 | 95.2 | (80.1-112.2) |
| Female | 21 | 19.7 | 106.6 | (66.0-163.0) |  | Female | 131 | 152.3 | 86.0 | (71.9-102.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

310

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 3 | 10.8 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 6 | 12.2 | 49.4 | (18.0-107.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

311

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 6.0 | 99.7 | (36.4-217.1) |  | Male | 5 | 4.4 | 113.2 | (36.5-264.2) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 4 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 7 | 4.0 | 177.0 | (70.9-364.6) |
| Female | 38 | 31.1 | 122.1 | (86.4-167.6) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 7.1 | 98.0 | (39.3-202.0) |  |  |  |  |  |  |
| Female | 4 | 7.1 | nc | (nc-nc) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 20 | 26.1 | 76.7 | (46.8-118.5) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 4.2 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 5 | 6.2 | 81.1 | (26.1-189.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 2.6 | 228.5 | (83.4-497.4) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 14 | 7.0 | 199.4 | (108.9-334.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 11.6 | 103.1 | (53.2-180.1) |  | Male | 86 | 92.4 | 93.1 | (74.5-115.0) |
| Female | 12 | 12.9 | 93.1 | (48.1-162.7) |  | Female | 108 | 97.9 | 110.4 | (90.5-133.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

312

# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 12.5 | 128.0 | (73.1-207.9) |  | Male | 13 | 8.6 | 150.7 | (80.1-257.6) |
| Female | 3 | 4.9 | nc | (nc-nc) |  | Female | 4 | 7.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 7 | 7.7 | 90.5 | (36.3-186.5) |
| Female | 61 | 58.4 | 104.4 | (79.9-134.1) |  | Female | 5 | 7.1 | 70.5 | (22.7-164.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 6.6 | 165.8 | (82.7-296.8) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 14.3 | 111.7 | (63.8-181.3) |  |  |  |  |  |  |
| Female | 15 | 15.3 | 98.2 | (54.9-162.0) |  | Female | 4 | 5.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 5 | 5.0 | 100.4 | (32.4-234.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 58 | 46.3 | 125.3 | (95.1-162.0) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 7.6 | 144.0 | (71.8-257.6) |  | Male | 5 | 3.1 | 163.3 | (52.6-381.1) |
| Female | 5 | 4.5 | 110.8 | (35.7-258.5) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 5.3 | 132.4 | (53.0-272.8) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 6 | 4.1 | 145.8 | (53.2-317.3) |  | Female | 9 | 10.7 | 84.4 | (38.5-160.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 13 | 13.3 | 98.1 | (52.2-167.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 22.9 | 126.8 | (84.9-182.1) |  | Male | 219 | 176.3 | 124.2 | (108.3-141.8) |
| Female | 23 | 26.3 | 87.4 | (55.4-131.2) |  | Female | 176 | 192.6 | 91.4 | (78.4-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

313

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 29.0 | 110.3 | (75.4-155.7) |  | Male | 27 | 19.0 | 142.2 | (93.7-206.9) |
| Female | 8 | 9.0 | 88.9 | (38.3-175.1) |  | Female | 26 | 13.8 | 188.4 | (123.0-276.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 5.6 | 142.8 | (61.5-281.3) |  | Male | 3 | 6.0 | nc | (nc-nc) |
| Female | 8 | 4.3 | 187.1 | (80.6-368.8) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 10 | 16.8 | 59.6 | (28.5-109.7) |
| Female | 125 | 109.1 | 114.6 | (95.4-136.5) |  | Female | 18 | 13.0 | 138.3 | (81.9-218.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 13.7 | 94.8 | (50.5-162.2) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 4 | 5.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 31.0 | 106.4 | (73.2-149.4) |  |  |  |  |  |  |
| Female | 34 | 27.3 | 124.7 | (86.4-174.3) |  | Female | 6 | 9.6 | 62.6 | (22.9-136.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.8 | nc | (nc-nc) |  | Male | 7 | 10.3 | 68.0 | (27.2-140.1) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 11 | 9.0 | 122.6 | (61.1-219.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 76 | 100.2 | 75.8 | (59.8-94.9) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 16.2 | 49.4 | (21.3-97.4) |  | Male | 5 | 6.8 | 73.1 | (23.6-170.6) |
| Female | 9 | 8.4 | 107.0 | (48.8-203.2) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 4.6 | 108.2 | (34.9-252.5) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 11.6 | 86.2 | (41.3-158.6) |  | Male | 5 | 7.4 | 67.7 | (21.8-158.0) |
| Female | 6 | 7.6 | 79.4 | (29.0-172.8) |  | Female | 22 | 21.0 | 104.7 | (65.6-158.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 10.4 | 57.8 | (21.1-125.9) |  |  |  |  |  |  |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 17 | 25.1 | 67.6 | (39.4-108.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 52.9 | 73.7 | (52.4-100.7) |  | Male | 323 | 386.0 | 83.7 | (74.8-93.3) |
| Female | 58 | 48.7 | 119.1 | (90.4-154.0) |  | Female | 396 | 358.0 | 110.6 | (100.0-122.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

314

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 7 | 8.2 | 85.1 | (34.1-175.3) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 2.1 | 292.0 | (106.6-635.7) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 10.1 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 6 | 2.0 | 298.9 | (109.1-650.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 4.7 | 127.0 | (46.4-276.4) |  | Male | 26 | 35.0 | 74.3 | (48.5-108.9) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 30 | 26.9 | 111.3 | (75.1-158.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

315